The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.
Novartis Venture Fund and Hikma Ventures led the Series A round. Correlation Ventures, Adaptive Healthcare Fund, Vega Ventures and 415 Ventures also took part in the round.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.